Bright lights, big milestone. β¨
CTx001 is officially headed into the clinic!
@ComplementTx celebrates FDA IND clearance in the heart of Times Square β lighting up the @Nasdaq tower for the second time. π§¬π
π° Media coverage roundup β¬οΈ
#INDClearance#GeneTherapy#BiotechNews
CTx001 is designed to modulate both classical and alternative complement pathways using a truncated CR1 (mini-CR1), delivered through AAV. A potentially durable, one-time treatment for GA, and this is just the start.
#Biotech#AMD#GeneTherapy#GeographicAtrophy#ClinicalTrial
π Big milestone for @ComplementTx:
Weβve received FDA IND clearance for CTx001, our lead gene therapy for Geographic Atrophy (GA).
Weβre now entering the clinic with Opti-GAIN, a first-in-human Phase I/II trial.
A huge step for the team, and for patients.
#INDClearance#CTx001
Very pleased to present this online Tutorial around the role of the Complement System in Disease in conjunction with the Stephen J Ryan Initiative for Macular Research (RIMR) and the Doheny Eye Institute
https://t.co/6oktLRtgXW via @YouTube#complement#Macula@DohenyEye
Great to see @ComplementTx gaining recognition for its work on the Complement Precision Medicine (CPM) platform. Patient stratification should be a major focus for clinical success. @RDUnwin #complementbiology#complementsystem#immunology
https://t.co/zK2fWWLFOO
π’The first patient enrolled in our i-GAIN Natural History Study!
We will be recruiting 250 patients with geographic atrophy (#GA) secondary to age-related macular degeneration (#AMD) across the UK and US over the next 12 months.
Find out more here:Β https://t.co/zIYknUs64g
A comprehensive review by @ProfClark M. Ueffing et al discusses the role of #complementbiology in #ocular disease, provides overview of #therapeutics & raises awareness on #time of intervention, proper #delivery routes & #patient selection
Worth reading!
https://t.co/CWp1c0ZLpR